Sarah Cannon Research Institute Grows Network with Addition of Mary Crowley Cancer Research
Sarah Cannon Research Institute shared on LinkedIn:
“We are excited to announce a significant expansion in our network at Sarah Cannon Research Institute (SCRI) with the acquisition of Mary Crowley Cancer Research, a leader in early-phase clinical research based in Dallas, Texas. This strategic partnership enhances our ability to provide cutting-edge clinical trials and innovative treatments to patients in North Texas, right in their communities.
With over 25 years of pioneering research and more than 800 clinical trials conducted, Mary Crowley Cancer Research brings a wealth of expertise and a shared commitment to advancing cancer treatment. As SCRI at Mary Crowley, we will continue to work closely with Texas Oncology physicians, enhancing our research capabilities and patient care through Genospace, our personalized medicine platform.
Join us in welcoming Mary Crowley Cancer Research to SCRI as we strive to transform lives and expand access to therapies.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023